Dr. Bharatt Chowrira

Biography

Dr. Chowrira has a strong track record in the biopharmaceutical industry with more than 20 years of experience, combining a unique blend of research, corporate development, operations, financing, legal and licensing expertise. Dr. Chowrira is currently the President of Synlogic Inc., a U.S. biopharmaceutical company focused on synthetic biotics, where he has overseen and managed corporate and business development, alliance management, and financial and legal operations since September 2015. Prior to joining Synlogic, Dr. Chowrira was the Chief Operating Officer of Auspex Pharmaceuticals, which was acquired by Teva Pharmaceuticals in the spring of 2015. Previously, he was President and Chief Executive Officer of Addex Therapeutics, a biotechnology company publicly‐traded on the SIX Swiss Exchange. Before that, he held various leadership and management positions at Nektar Therapeutics, Merck & Co., Sirna Therapeutics, (acquired by Merck & Co.) and Ribozyme Pharmaceuticals. Dr. Chowrira has a J.D. from the University of Denver’s Sturm College of Law, a Ph.D. in Molecular Biology from the University of Vermont College of Medicine, a M.S. in Molecular Biology from Illinois State University, and a B.S. in Microbiology from the University of Agricultural Sciences, Bangalore, India. Dr. Chowrira has a strong track record in the biopharmaceutical industry with more than 20 years of experience, combining a unique blend of research, corporate development, operations, financing, legal and licensing expertise. Dr. Chowrira is currently the President of Synlogic Inc., a U.S. biopharmaceutical company focused on synthetic biotics, where he has overseen and managed corporate and business development, alliance management, and financial and legal operations since September 2015. Prior to joining Synlogic, Dr. Chowrira was the Chief Operating Officer of Auspex Pharmaceuticals, which was acquired by Teva Pharmaceuticals in the spring of 2015. Previously, he was President and Chief Executive Officer of Addex Therapeutics, a biotechnology company publicly‐traded on the SIX Swiss Exchange. Before that, he held various leadership and management positions at Nektar Therapeutics, Merck & Co., Sirna Therapeutics, (acquired by Merck & Co.) and Ribozyme Pharmaceuticals. Dr. Chowrira has a J.D. from the University of Denver’s Sturm College of Law, a Ph.D. in Molecular Biology from the University of Vermont College of Medicine, a M.S. in Molecular Biology from Illinois State University, and a B.S. in Microbiology from the University of Agricultural Sciences, Bangalore, India.

Research Interest

biopharmaceutical industry